Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M)

Diana Santos1,2, Teresa Coelho3, Miguel Alves-Ferreira1,2

  • 1UnIGENe, IBMC, Institute for Molecular and Cell Biology, and Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.

Insights

Genetic variations in APCS, RBP4, and AR genes influence the age of onset for Familial Amyloid Polyneuropathy ATTRV30M, offering insights for genetic counseling and therapies.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Familial amyloid polyneuropathy (FAP) ATTRV30M, caused by transthyretin gene mutations, exhibits significant variability in age of onset (AO).
  • Previous research suggests genetic modifiers influence FAP ATTRV30M's AO, with notable gender-based differences observed in Portuguese populations.

Purpose of the Study:

  • To investigate the role of APCS and RBP4 genes in modifying AO for FAP ATTRV30M.
  • To examine the involvement of sex-linked genes, specifically AR and HSD17B1, as AO modifiers in Portuguese FAP ATTRV30M families.

Main Methods:

  • Genotyping of 18 tagging SNPs from APCS, RBP4, AR, and HSD17B1, plus 5 additional SNPs from APCS and RBP4.
  • Utilized generalized estimating equations (GEEs) to analyze age of onset data from 318 FAP ATTRV30M patients, accounting for familial non-independency.

Main Results:

  • APCS and RBP4 gene variants were associated with later age of onset.
  • A specific RBP4 SNP (rs11187545) was linked to an earlier age of onset.
  • AR gene SNPs demonstrated associations with both early and late age of onset in both male and female patients.

Conclusions:

  • The study confirms the role of APCS and RBP4 as AO modifiers in FAP ATTRV30M.
  • It provides the first evidence for the AR gene's contribution to AO variation in both sexes.
  • These findings have potential implications for genetic counseling and the development of targeted therapeutic strategies for FAP ATTRV30M.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.0K